Eisai's Lorqess Setback Puts Focus Squarely on Eribulin
This article was originally published in PharmAsia News
TOKYO - Eisai's recently acquired weight loss drug Lorqess appears set for failure in the hands of U.S. FDA, and while approval rejection would have a small direct impact on the company, the pending approval of eribulin becomes even more vital to a company trying to offset upcoming years of patent losses
You may also be interested in...
Committee votes 9 to 5 vote against approval of Arena's weight loss drug, troubled that the study populations didn't reflect the real world.
Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2
Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)
TOKYO - Japanese pharma are responding to patent cliffs much like their Western counterparts, through lifecycle management, cost containment and increased focus on emerging markets. In Part 1 of PharmAsia News' roundup of the Japanese Q1 earnings season, Astellas and Eisai respond to patent loss of blockbuster products by highlighting product development milestones and patent extensions